These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11771213)

  • 1. Low level laser treatment of primary and secondary Raynaud's phenomenon.
    al-Awami M; Schillinger M; Gschwandtner ME; Maca T; Haumer M; Minar E
    Vasa; 2001 Nov; 30(4):281-4. PubMed ID: 11771213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low level laser therapy for treatment of primary and secondary Raynaud's phenomenon.
    al-Awami M; Schillinger M; Maca T; Pollanz S; Minar E
    Vasa; 2004 Feb; 33(1):25-9. PubMed ID: 15061044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon.
    Hirschl M; Katzenschlager R; Ammer K; Melnizky P; Rathkolb O; Kundi M
    Vasa; 2002 May; 31(2):91-4. PubMed ID: 12099151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study.
    Hirschl M; Katzenschlager R; Francesconi C; Kundi M
    J Rheumatol; 2004 Dec; 31(12):2408-12. PubMed ID: 15570642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
    J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon.
    Kristensen JK; Engelhart M; Nielsen T
    Acta Derm Venereol; 1983; 63(1):43-7. PubMed ID: 6191488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
    Wise RA; Wigley F
    J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon.
    Schuhfried O; Vacariu G; Lang T; Korpan M; Kiener HP; Fialka-Moser V
    Arch Phys Med Rehabil; 2000 Apr; 81(4):495-9. PubMed ID: 10768542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laser Doppler flowmeter and standardized thermal test in normals and Raynaud's phenomenon.
    Boccalon HJ; Marguery MC; Ginestet MC; Puel PF
    Int Angiol; 1987; 6(2):107-18. PubMed ID: 3323348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between subjective vasospastic complaints and finger blood flow measurements in Raynaud's phenomenon.
    Leesmans E; Bartelink ML; Wollersheim H; Thien T
    Neth J Med; 1993 Aug; 43(1-2):13-7. PubMed ID: 8232689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.